Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York. Show more

7 Times Square, New York, NY, 10036, United States

https://dianthustx.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

5.537B

52 Wk Range

$18.08 - $102.37

Previous Close

$101.28

Open

$100.01

Volume

277,326

Day Range

$98.10 - $102.34

Enterprise Value

4.425B

Cash

1.111B

Avg Qtr Burn

-28.86M

Insider Ownership

0.13%

Institutional Own.

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Claseprubart (DNTH103) Details Generalized Myasthenia Gravis (gMG)	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Claseprubart (DNTH103) Details Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Claseprubart (DNTH103) Details Multifocal Motor Neuropathy (MMN)	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MGTA-145 + plerixafor Details Multiple myeloma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LBL-047 (DNTH212) (BDCA2/TACI Inhibitor) Details Systemic Lupus Erythematosus	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.